Israeli co Bonus BioGroup reports Covid-19 treatment success

In an Israeli trial, severely ill patients treated with Bonus BioGroup's stem-cell based product MesenCure showed significant improvement, reported Globes.

The 10-patient trial found improvement in several health parameters the first time the treatment was administered, and further improvement as treatment continued.

The study did not include a control group, but the parameters of each patient after treatment were compared with their highest readings, Globes said, adding that MesenCure works on the hyper-inflammation mechanism.

Results show that the level of inflammatory protein CRP in the patients' blood fell by 29% to 34%, and the level of creatinine kinase fell by 20% to 22%.

In addition, radiographs showed a decrease in the area of diffuse lung inflammation in patients treated with MesenCure.

Principal investigator Shadi Hamoud said the findings "are significantly better compared to the results achieved with other therapies." Bonus BioGroup is now embarking on a trial of 50 additional patients.